Study: Lower Major Complication Risk with Medtronic’s Micra Compared to Conventional Pacers
Thursday, June 9, 2016
Source: Mass Device
Medtronic (NYSE:MDT) today released new results from a clinical trial of its leadless Micra transcatheter pacing system, touting significantly reduced major complication risks compared to conventional pacing systems.
The Micra transcatheter pacing system, which at 1/10th the size of a conventional pacemaker is roughly the size of a large vitamin, is designed to be implanted via catheter in the right ventricle to deliver single-chamber pacing, Medtronic said. The Micra device has an estimated 12-year battery life and is approved as safe for full-body MRI scans.